Prof. Yingfen Ying | Tumors | Women Researcher Award

Prof. Yingfen Ying | Tumors | Women Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

Scopus

PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL 👩‍⚕️🌍

EARLY ACADEMIC PURSUITS 🎓✨

Professor Yingfen Ying embarked on her academic journey with a strong focus on medical sciences, demonstrating an early aptitude for research and clinical excellence. Her academic foundation was fortified through rigorous education at Wenzhou Medical University, where she gained critical knowledge and skills that paved the way for her distinguished career. She further enriched her expertise as a visiting scholar at the University of British Columbia in Canada, a testament to her global academic vision.

PROFESSIONAL ENDEAVORS 💼🏥

Professor Ying has made significant strides as an Associate Chief Physician and master’s supervisor at Wenzhou Medical University. Her roles extend to various esteemed positions, including:

  • Member of the Obstetrics and Gynecology Rehabilitation Committee, Chinese Rehabilitation Medicine Association.
  • Vice Chairwoman of the Youth Committee, Reproductive Medicine Branch, Zhejiang Society of Traditional Chinese and Western Medicine.
  • Member of the Obstetrics and Gynecology Branch, Zhejiang Society of Translational Medicine.
    She is also affiliated with prominent international organizations, such as the American Society of Reproductive Medicine and the European Society of Human Reproduction and Embryology.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬📚

Professor Ying’s primary research interests center on the mechanistic study of environmental endocrine disruptors and reproductive endocrine diseases. Her investigations delve into the interplay between environmental factors and hormonal imbalances, significantly advancing our understanding of infertility diseases. She has led multiple national and international research projects, including those funded by the National Natural Science Foundation of China.

IMPACT AND INFLUENCE 🌟🌏

Professor Ying’s work has had far-reaching impacts in the field of reproductive medicine. She has authored nearly 30 SCI-indexed papers, contributing valuable insights and advancements to the global medical community. Her research continues to influence clinical practices and guide innovative therapeutic approaches for infertility.

ACADEMIC CITES AND PATENT ACHIEVEMENTS 📜🔑

Professor Ying’s extensive research portfolio has garnered numerous citations in high-impact journals. Additionally, she holds a European patent, exemplifying her contributions to advancing medical technology and treatment methodologies on a global scale.

LEGACY AND FUTURE CONTRIBUTIONS 🌟🚀

As a trailblazer in reproductive medicine, Professor Yingfen Ying’s legacy is defined by her commitment to advancing medical science, mentoring future generations, and improving patient outcomes. Her ongoing projects and international collaborations promise continued breakthroughs, ensuring her work remains at the forefront of reproductive health and endocrine research.

ADDITIONAL HIGHLIGHTS 🌐📖

  • Active member of youth committees in Zhejiang’s medical and scientific communities, fostering innovation and development among emerging scholars.
  • Her dedication to integrating traditional Chinese and Western medicine highlights a holistic approach to patient care and research.
  • International affiliations reflect her commitment to global medical advancements, strengthening ties between diverse medical communities.

CONCLUSION 🌟🏆

Professor Yingfen Ying exemplifies excellence in the fields of reproductive medicine and endocrine research. Her dedication to uncovering the mechanisms of infertility diseases and environmental endocrine disruptors has advanced both science and clinical practice. Through her leadership roles, impactful publications, and international collaborations, she has established herself as a global authority and advocate for holistic and innovative approaches to healthcare.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Halogen atoms determine the inhibitory potency of halogenated bisphenol A derivatives on human and rat placental 11β-hydroxysteroid dehydrogenase 2
    Authors: Shi, L., Zhang, B., Ying, Y., Ge, R.-S., Liu, Y.
    Journal: Food and Chemical Toxicology
    Year: 2023

 

  • Title: Inhibitory effects of parabens on human and rat 17β-hydroxysteroid dehydrogenase 1: Mechanisms of action and impact on hormone synthesis
    Authors: Chen, Z., Gong, C., Tang, Y., Ge, R.-S., Ying, Y.
    Journal: Toxicology
    Year: 2024

 

  • Title: Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis
    Authors: Wen, C., Chen, H., Tang, Y., Chen, C., Chen, S.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2024

 

  • Title: Leydig cell development in pubertal male rats is blocked by perfluorotetradecanoic acid through decreasing AMPK-mTOR-autophagy pathway
    Authors: Tang, Y., Shi, L., Wang, S., Ge, R.-S., Ying, Y.
    Journal: Toxicology Letters
    Year: 2023

 

  • Title: Structure-activity relationship and in silico docking analysis of dicarboximide fungicides on 17β-hydroxysteroid dehydrogenase 1 of human, rat, and pig
    Authors: Chen, H., Chen, S., Tang, Y., Ge, R.-S., Duan, P.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2025

Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Prof Dr. Yinyuan Ding | Tumorigenesis | Best Researcher Award

Chongqing Medical University | China

Author Profile

Scopus

ORCID ID

Professor Yinyuan Ding

🌟 Professor of Oncology
🏥 Chongqing Medical University

🎓 Academic and Professional Background:

Professor Yinyuan Ding obtained a Ph.D. from Peking University in 2011 and pursued postdoctoral training at UT Southwestern Medical Center, where he was later promoted to Assistant Professor in 2018. In 2019, he returned to China and joined Chongqing Medical University as a professor. His research explores tumorigenesis and glucolipid metabolic disorders, focusing on the LRP1 receptor’s role in liver and vascular signaling, with implications for novel treatments for Hepatocellular Carcinoma (HCC) and Metabolic Associated Steatohepatitis-Liver Disease (MASLD).

🔬 Research and Innovations:

  • Principal Investigator
    2023-2026: “The role of LRP1 in hepatic glucose metabolism and HCC progression” (National Natural Science Foundation of China)
    2021: “The role of Asprosin in hepatocellular carcinoma” (Chongqing Municipal Human Resources Bureau)

 

  • Participant
    2015-2020: “VLDL and ApoE receptors metabolism” (NIH-NHLBI)
    2011-2015: “Cell signaling and cholesterol-lipoprotein receptors” (NIH)

📚 Journals Published:

Advanced Science, Elife, Science Signaling, EBioMedicine, JBC

🤝 Collaborations:

Collaborates with Joachim Herz (UT Southwestern Medical Center, USA)

👥 Professional Memberships:

Director of the China Branch, International Atherosclerosis Society

🧬 Areas of Research:

  • Oncology
  • Tumorigenesis
  • Hepatology
  • Lipoprotein & Lipid Research

📝 Contributions:

Professor Ding’s groundbreaking research on LRP1 has revealed its multifaceted roles in regulating cholesterol and glucose metabolism. His work identified a critical mechanism by which LRP1 affects hepatic insulin resistance, dyslipidemia, and HCC progression. This novel insight into LRP1’s function opens pathways for innovative therapeutic strategies for cancer and metabolic disorders.

Conclusion:

In summary, Professor Yinyuan Ding is a distinguished expert in oncology and hepatology, with a strong focus on the molecular mechanisms of tumorigenesis and lipid metabolism disorders. His innovative research on LRP1 has led to significant breakthroughs in understanding liver disease and cancer progression, paving the way for novel therapeutic strategies. With a wealth of experience from top institutions and numerous prestigious publications and patents, Professor Ding continues to make impactful contributions to the field of cancer research, driving advancements in both basic science and clinical applications. 🌟

📊🔬NOTABLE PUBLICATION:

1. LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice

  • Authors: Guo, X., Pu, J., Tang, Z., Liu, T., Ding, Y.
  • Journal: Animal Models and Experimental Medicine
  • Year: 2024

2. Erratum: Correction: LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis

  • Authors: Xian, X., Ding, Y., Dieckmann, M., Tsai, S., Herz, J.
  • Journal: eLife
  • Year: 2017 (Erratum published in 2024)

3. Loss of LRP1 Promotes Hepatocellular Carcinoma Progression via UFL1-Mediated Activation of NF-κB Signaling

  • Authors: Guo, X., Yang, F., Liu, T., Herz, J., Ding, Y.
  • Journal: Advanced Science
  • Year: 2024

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

🌟 Distinguished Scientist Award: Dr. Chen Wang 🌟

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

📚 Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

🧬 Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

🏆 Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

🌐 Professional Links

📄 Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

📊🔬Notable Publication: